Shandong Junxiu Biotechnology Co., Ltd, a China-based maker of implantable regenerative medicine devices, has raised RMB 45 million (USD 6.2 million) in a Series B financing round. The round was led by Shenzhen Capital Group, with participation from Qianhai FOF, Huantong Venture Capital, and other investors. The proceeds will be used to support clinical studies, market promotion for commercialized products, subsidiary development, and talent recruitment.
Company Background and Innovation
Junxiu Biotechnology is known for its innovative “acellular matrix peripheral nerve repair membrane,” which it describes as the world’s first homologous and heterogeneous peripheral nerve injury repair product. The company is also developing dozens of implantable medical devices, covering a broad range of regenerative medicine fields, including nerve repair, stomatology, bone repair, reproductive health, and sports medicine.
Future Development Plans
With the new funding, Junxiu Biotechnology aims to accelerate the development and commercialization of its product pipeline. The company plans to expand its market presence through strategic initiatives, enhance its subsidiaries’ capabilities, and attract top talent to drive innovation and growth in the field of implantable regenerative devices.-Fineline Info & Tech
